SIRT1 and acute promyelocytic leukemia: Such compounds were evaluated in p300, PCAF, SIRT1/2, EZH2 and CARM1 enzyme assays, and in NB4 APL, U937 AML, MCF-7 breast cancer and SH-SY5Y neuroblastoma cells, to determine their effects in cell cycle phases and apoptosis induction when used at 5 μM for 30 h.